secwatch / observer
8-K filed September 25, 2024, 7:59 PM ET ticker CERO CIK 0001870404
leadership confidence high sentiment negative materiality 0.75

CERo raises $1.2M, CEO and CTO resign; CER-1236 on clinical hold

CERO THERAPEUTICS HOLDINGS, INC.

item 1.01item 3.02item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Daniel Corey

Chief Technology Officer
CERO · CERO THERAPEUTICS HOLDINGS, INC.
Effective
2024-09-23
Filed
September 25, 2024, 7:59 PM ET
On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
Appointed (interim)

Chris Ehrlich

Interim Chairman and Chief Executive Officer
CERO · CERO THERAPEUTICS HOLDINGS, INC.
Filed
September 25, 2024, 7:59 PM ET
Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.
Departed

Daniel Corey

director
CERO · CERO THERAPEUTICS HOLDINGS, INC.
Effective
2024-09-23
Filed
September 25, 2024, 7:59 PM ET
On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
Departed (interim)

Brian G. Atwood

Chief Executive Officer
CERO · CERO THERAPEUTICS HOLDINGS, INC.
Effective
2024-09-30
Successor
Chris Ehrlich
Filed
September 25, 2024, 7:59 PM ET
On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Corey resigned as Chief Technology Officer at CERO THERAPEUTICS HOLDINGS, INC..

Action
resigned
Role
Chief Technology Officer
Exact text from the filing
On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Ehrlich was appointed as Interim Chairman and Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..

Action
appointed
Role
Interim Chairman and Chief Executive Officer
Exact text from the filing
Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Corey resigned as director at CERO THERAPEUTICS HOLDINGS, INC..

Action
resigned
Role
director
Exact text from the filing
On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brian G. Atwood resigned as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..

Action
resigned
Role
Chief Executive Officer
Exact text from the filing
On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.
View on SEC.gov

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR
accession 0001213900-24-081792
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.